Picture of Sartorius Stedim Biotech SA logo

DIM — Sartorius Stedim Biotech SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Brief: Sartorius Stedim Biotech Prelim. FY Underlying EBITDA At EUR 779 Mln

Jan 28 (Reuters) - Sartorius Stedim Biotech SA
 STDM.PA :
    * PUBLISHES PRELIMINARY, UNAUDITED RESULTS FOR FISCAL 2024
    * 2024 REVENUE AND PROFITABILITY TARGETS FULLY MET
    * CAUTIOUSLY POSITIVE OUTLOOK FOR 2025: PROFITABLE GROWTH
EXPECTED
    * 2024 UNDERLYING EBITDA OF 779 MILLION EUROS, RESULTING
MARGIN AT
28.0 PERCENT; NET PROFIT OF 175 MILLION EUROS
    * NET OPERATING CASH FLOW UP 9.2 PERCENT TO 815 MILLION
EUROS
    * FY SALES REVENUE AT 2,780 MILLION EUROS, IN CONSTANT
CURRENCIES
UP +0.6 PERCENT INCLUDING NON-ORGANIC CONTRIBUTION

Source text:  ID:nEQ2LkFbTa 
Further company coverage:  STDM.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on Sartorius Stedim Biotech SA

See all news